SCHEMBL4886360

SCHEMBL4886360

C[C@]12CC=C(O)CC1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)C(=O)CC[C@@H]12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 4/20 0.44
AKR1B10 O60218 2/20 0.44
AKR1B1 P15121 2/20 0.44
OR51E2 Q9H255 1/20 0.44
GPBAR1 Q8TDU6 5/20 0.43
HSD17B3 P37058 5/20 0.43
LMNA P02545 4/20 0.43
CYP3A4 P08684 4/20 0.43
SHBG P04278 3/20 0.43
SERPINA6 P08185 3/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
PMP22 Q01453 2/20 0.43
G6PD P11413 2/20 0.43
TSHR P16473 2/20 0.43
MAPK1 P28482 1/20 0.43
CYP2D6 P10635 1/20 0.43
NFKB1 P19838 1/20 0.43
CYP2C19 P33261 1/20 0.43
GUSB P08236 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6940266 0.81 AKR1B10 (0.65) CYP19A1AKR1B10AKR1B1OR51E2GPBAR1
SCHEMBL19270194 0.81 AKR1B10 (0.65) CYP19A1AKR1B10AKR1B1OR51E2GPBAR1
SCHEMBL20058396 0.81 AKR1B10 (0.65) CYP19A1AKR1B10AKR1B1OR51E2GPBAR1
SCHEMBL6940263 0.81 AKR1B10 (0.65) CYP19A1AKR1B10AKR1B1OR51E2GPBAR1
SCHEMBL16407556 0.81 CYP19A1 (0.64) CYP19A1AKR1B10AKR1B1OR51E2GPBAR1
SCHEMBL17697306 0.81 AKR1B10 (0.65) CYP19A1AKR1B10AKR1B1OR51E2GPBAR1
SCHEMBL6943587 0.81 AKR1B10 (0.65) CYP19A1AKR1B10AKR1B1OR51E2GPBAR1
SCHEMBL7805788 0.81 AKR1B10 (0.65) CYP19A1AKR1B10AKR1B1OR51E2GPBAR1
SCHEMBL17361278 0.81 AKR1B10 (0.65) CYP19A1AKR1B10AKR1B1OR51E2GPBAR1
SCHEMBL4585718 0.81 CYP19A1 (0.64) CYP19A1AKR1B10AKR1B1OR51E2GPBAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080033046-A1 Treatment of myocardial infarction with 11HSD1 inhibitors UNIVERSITY OF EDINBURGH (GB) 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033046-A1 Treatment of myocardial infarction with 11HSD1 inhibitors HSD11B1, HSD11B2, CYP11B1 CYP19A1 166/4885AKR1B10 236/4885AKR1B1 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.